5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 12, 2010, Pages 3526-3529

  Zhang, Nan ^a   Ayral Kaloustian, Semiramis ^a   Anderson, James T ^a   Nguyen, Thai ^a   Das, Sasmita ^a   Venkatesan, Aranapakam M ^a   Brooijmans, Natasja ^a   Lucas, Judy ^a   Yu, Ker ^a   Hollander, Irwin ^a   Mallon, Robert ^a  

^a WYETH RESEARCH   (United States)

Author keywords

mTOR inhibitor; PI3K inhibitor

Indexed keywords

4 METHYLPIPERAZIN 1 YL; 4 MORPHOLINYL; [2 (DIMETHYLAMINO)ETHYL]METHYLAMINO; ANTINEOPLASTIC AGENT; BINEDALINE; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER MODEL; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; TUMOR VOLUME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BENZOFURANS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MICROSOMES; PROTEIN-SERINE-THREONINE KINASES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR BURDEN; UREA;

EID: 77954213226     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.139     Document Type: Article

References (12)

1. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Nat. Rev. Drug Disc. 8 2009 627
2. A. Carnero Expert Opin. Invest. Drugs 18 2009 1265
3. For review of PI3K inhibitors in oncology, see J.C. Verheijen, and A. Zask Drugs Future 32 2007 537
4. For review of mTOR inhibitors in oncology, see J.C. Verheijen, K. Yu, and A. Zask Ann. Rep. Med. Chem. 43 2008 189
5. M.E. Feldman, B. Apsel, A. Uotila, R. Loewith, Z.A. Knight, D. Ruggero, and K.M. Shokat PLoS Biol. 7 2009 371
6. X. Wang, P. Yue, Y.A. Kim, H. Fu, F.R. Khuri, and S.-Y. Sun Drugs Future 68 2008 7409
7. M.G. Bursavich, N. Brooijmans, L. Feldberg, I. Hollander, S. Kim, S. Lombardi, K. Park, R. Mallon, and A.M. Gilbert Bioorg. Med. Chem. Lett. 20 2010 2586
8. H.-R. Tsou, G. MacEwan, G. Birnberg, G. Grosu, M.G. Bursavich, J. Bard, N. Brooijmans, L. Toral-Barza, I. Hollander, T.S. Mansour, S. Ayral-Kaloustian, and K. Yu Bioorg. Med. Chem. Lett. 20 2010 2321
9. H.-R. Tsou, G. MacEwan, G. Birnberg, N. Zhang, N. Brooijmans, L. Toral-Barza, I. Hollander, S. Ayral-Kaloustian, and K. Yu Bioorg. Med. Chem. Lett. 20 2010 2259
10. P.D. Johnson, and P.A. Aristoff J. Org. Chem. 55 1990 1374
11. A.M. Venkatesan, C.M. Dehnhardt, E. Delos Santos, Z. Chen, O. Dos Santos, S. Ayral-Kaloustian, G. Khafizova, N. Brooijmans, R. Mallon, I. Hollander, L. Feldberg, J. Lucas, K. Yu, J. Gibbons, R.T. Abraham, I. Chaudhary, and T.S. Mansour J. Med. Chem. 53 2010 2636
12. C.M. Dehnhardt, A.M. Venkatesan, E. Delos Santos, Z. Chen, O. Santos, S. Ayral-Kaloustian, N. Brooijmans, R. Mallon, I. Hollander, L. Feldberg, J. Lucas, I. Chaudhary, K. Yu, J. Gibbons, R. Abraham, and T.S. Mansour J. Med. Chem. 53 2010 798